Sarvodaya Healthcare, Transcell Oncologics partner to offer predictive genetic analysis
01 June 2022 | News
HEMATO PREGEN is one-of-its-kind Predictive Genetic Analysis of the genetic material (RNA/DNA) in our body to identify the genetic anomalies that cause up to 90% of genetic diseases in humans
Image Credit: Shutterstock
Sarvodaya Hospital, Faridabad and Transcell Oncologics, a stem cell technology-based biotech company in Hyderabad, have announced that HEMATO PREGEN, a comprehensive test providing predictive health signature analysis services from Transcell will now be available at Sarvodaya Medicentre at GK Enclave 1 in New Delhi.
HEMATO PREGEN provides analysis of 20,000+ genes, which are known as predictive biomarkers, covering 90 per cent of diseases resulting from gene anomalies.
The test is based on Next Generation/Whole Exome Sequencing (NGS/WES) and assessment by GenePoweRx, a homegrown trained Bioinformatics Engine with AI & ML tools and endorsed by Memorial Sloan Kettering Cancer Center, USA, in line with the Broad Institute’s human genome project. The report takes up to 45 days and a post-counselling session is offered at the clinic thereafter.
